ScreenerHero

LENZLENZ Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · lenz-tx.com
4.680USD-4.88%Mkt Cap: 147.05M $P/E: —

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and L…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap147.05M $
Enterprise Value-73.02M $
Revenue (TTM)21.48M $
Gross Profit18.67M $
Net Income (TTM)-82.13M $
Revenue/Share0.7020 USD
Last Price4.680 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees152
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.52
PEG—
EV/EBITDA0.54
EV/Revenue-3.40
P/S6.82
P/B0.67
EPS (TTM)-3.90
EPS (Forward)-3.08
52W Range
4.5350% of range50.40
52W High50.40 USD
52W Low4.535 USD
Profitability
Gross Margin97.81%
Oper. Margin-622.89%
EBITDA Margin0.00%
Profit Margin-430.25%
ROE-28.88%
ROA-26.85%
Growth
Revenue Growth9.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.17M $
CapEx (TTM)827.00K $
FCF Margin-331.79%
FCF Yield-48.46%
Net Debt-219.43M $
Net Debt/EBITDA1.62
Balance Sheet
Debt/Equity0.00
Current Ratio13.55
Quick Ratio12.91
Book Value/Sh6.979 USD
Cash/Share7.002 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 21, 2024
Splits
Last Split1:7
Split DateMar 22, 2024
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.00 USD
Upside (mean)+412.8%
Target Range7.000 USD – 60.00 USD
$7.000+412.8% to mean$60.00
# Analysts7
Ownership
Shares Out.31.42M
Float18.39M
Insiders2.65%
Institutions111.80%
Short Interest
Short Ratio10.7d
Short % Float59.47%
Short % Out.36.10%
Shares Short11.32M
Short (prev mo.)10.43M
Technical
SMA 505.513 (-15.1%)
SMA 20012.61 (-62.9%)
Beta1.63
S&P 52W Chg18.16%
Avg Vol (30d)930.09K
Avg Vol (10d)818.35K
Technical Indicators
RSI (14)38.3
MACD-0.2470
MACD Signal-0.2265
MACD Hist.-0.0205
BB Upper5.953 USD
BB Middle5.206 USD
BB Lower4.459 USD
BB Width28.70%
ATR (14)0.4271 USD
Vol Ratio (20d)0.56x